Compare Adaptive Biotechnologies Corp (ADPT) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Meta Platforms Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while Meta Platforms Inc trades at $604.83 (market cap $1.56T). The key difference: Meta Platforms Inc is far larger — about 468.5× Adaptive Biotechnologies Corp's market cap, and Meta Platforms Inc pays a 0.34% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | META | |
|---|---|---|
Market Cap | $3.33B | $1.56T |
Sector | Health | Media |
52-Week High | $22.37 | $790.00 |
52-Week Low | $10.24 | $525.72 |
Enterprise Value | $3.19B | $1.57T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
META trades at $605.36, up 0.84% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income margin of 32.84%, and improving cash flow trends. Recent AI developments including the Muse Spark launch and positive analyst sentiment support growth prospects despite legal challenges.
META presents a compelling investment case with strong profitability, AI innovation leadership, and analyst consensus pointing to significant upside. Key risks include regulatory lawsuits and high capital expenditures, but the company's financial strength and market position suggest continued growth potential for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
